A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
Clinical Infectious Diseases2009Vol. 48(12), pp. 1676–1684
Citations Over TimeTop 1% of 2009 papers
Robert F. Betts, Márcio Nucci, Deepak Talwar, Marcelo Gareca, Flávio Queiroz‐Telles, Roger Bedimo, Raoul Herbrecht, Guillermo M. Ruiz‐Palacios, Jo‐Anne H. Young, John W. Baddley, Kim M. Strohmaier, Kimberly A. Tucker, Arlene F. Taylor, Nicholas A. Kartsonis, Caspofungin High‐Dose Study Group
Abstract
Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
Related Papers
- → Caspofungin(2003)292 cited
- → In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method(2022)8 cited
- → The pharmacology and clinical use of caspofungin(2007)28 cited
- → Addition of Caspofungin to Fluconazole Does Not Improve Outcome in Murine Candidiasis(2003)39 cited
- → Caspofungin in the treatment of invasive fungal infections(2005)2 cited